Skip to content
Advertisement

FILE - This Thursday, July 9, 2015, file photo shows the headquarters of Gilead Sciences in Foster City, Calif. Gilead Sciences will pay $11.9 billion in cash to buy Kite Pharma and plant a stake in an emerging area of cancer treatments that train a patient’s immune cells to attack tumors. Kite’s portfolio of potential treatments includes one for some forms of the blood cancer lymphoma that could receive U.S. regulatory approval later in 2017. (AP Photo/Eric Risberg, File)

FILE - This Thursday, July 9, 2015, file photo shows the headquarters of Gilead Sciences in Foster City, Calif. Gilead Sciences will pay $11.9 billion in cash to buy Kite Pharma and plant a stake in an emerging area of cancer treatments that train a patient’s immune cells to attack tumors. Kite’s portfolio of potential treatments includes one for some forms of the blood cancer lymphoma that could receive U.S. regulatory approval later in 2017. (AP Photo/Eric Risberg, File)

Featured Photo Galleries

01-Army parade.png

Military parade celebrates Army’s 250th

Cheers and chants rang out Saturday from a crowd of thousands as soldiers manned modern and historic tanks and aircraft for the Army’s 250th anniversary celebration in the District.

20250330 Sabatini-Caps-Sabres 001.jpg

Ovi scores goal 890, Caps lose to Sabres 8-5

Alexander Ovechkin scored goal number 890, but the Washington Capitals fell short, losing to the visiting Buffalo Sabres Sunday afternoon 8-5 at Capital One Arena in Washington D.C., March 30, 2025 (Photos for the Washington Times.)